Achieve is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine dependence.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 20 years. It is estimated that over 20 million people have used cytisinicline to help combat nicotine dependence.

Achieve’s focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. Smoking is currently the leading cause of preventable death and is responsible for over eight million people losing their lives annually worldwide.

Achieve is actively engaging in partnership discussions to enable the commercialization of cytisinicline.

We’d love to connect with you and discuss how we may be able to work together to make a significant impact on public health and end the nicotine addiction epidemic.

Contact us here